XZXiaoyi Zheng

Xiaoyi Zheng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xiaoyi Zheng has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Alexandre Gaudet

    Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Stanford, California

    1 shared publication
  • Angela Balistrieri

    Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Stanford, California

    1 shared publication
  • Avi Z. Rosenberg

    Department of Pathology, Johns Hopkins University School of Medicine

    1 shared publication
  • Brandon Ginley

    Department of Pathology and Anatomical Sciences, University at Buffalo–The State University of New York, Buffalo, New York

    1 shared publication
  • Briana Santo

    Department of Pathology and Anatomical Sciences, University at Buffalo–The State University of New York, Buffalo, New York

    1 shared publication
  • Catherine Li

    Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Stanford, California

    1 shared publication

Latest Publications

  • Endothelial Cell-Specific Molecule-1 Inhibits Albuminuria in Diabetic Mice

    by Xiaoyi Zheng, Lauren Higdon, Alexandre Gaudet, Manav Shah, Angela Balistrieri, Catherine Li, Patricia Nadai, Latha Palaniappan, Xiaoping Yang, Briana Santo, et al.

    Key Points: Circulating endothelial cell-specific molecule-1 (Esm-1) inversely correlates with diabetic kidney disease. Addition of Esm-1 in susceptible mice reduces albuminuria, and deletion of Esm-1 in resistant mice mildly worsens albuminuria. Esm-1 attenuates podocyte injury and select IFN signaling, highlighting innate immunity as a potential mechanism of kidney disease. Background: Diabetic kidney disease (DKD) is the most common cause of kidney failure in the world, and novel predictive biomarkers and molecular mechanisms of disease are needed. Endothelial cell-specific molecule-1 (Esm-1) is a secreted proteoglycan that attenuates inflammation. We previously identified that a glomerular deficiency of Esm-1 associates with more pronounced albuminuria and glomerular inflammation in DKD-susceptible relative to DKD-resistant mice, but its contribution to DKD remains unexplored. Methods: Using hydrodynamic tail-vein injection, we overexpress Esm-1 in DKD-susceptible DBA/2 mice and delete Esm-1 in DKD-resistant C57BL/6 mice to study the contribution of Esm-1 to DKD. We analyze clinical indices of DKD, leukocyte infiltration, podocytopenia, and extracellular matrix production. We also study transcriptomic changes to assess potential mechanisms of Esm-1 in glomeruli. Results: In DKD-susceptible mice, Esm-1 inversely correlates with albuminuria and glomerular leukocyte infiltration. We show that overexpression of Esm-1 reduces albuminuria and diabetes-induced podocyte injury, independent of changes in leukocyte infiltration. Using a complementary approach, we find that constitutive deletion of Esm-1 in DKD-resistant mice modestly increases the degree of diabetes-induced albuminuria versus wild-type controls. By glomerular RNAseq, we identify that Esm-1 attenuates expression of kidney disease–promoting and interferon (IFN)-related genes, including Ackr2 and Cxcl11. Conclusions: We demonstrate that, in DKD-susceptible mice, Esm-1 protects against diabetes-induced albuminuria and podocytopathy, possibly through select IFN signaling. Companion studies in patients with diabetes suggest a role of Esm-1 in human DKD.